EGFR and neoplasm: Additionally, when coupled with the epidermal growth factor receptor (EGFR) - targeting antibodies, sgPLK1-cLNPs was systemically and selectively disseminated to reach metastatic ovarian cancer cells allowing ~80% of gene editing, significant tumour growth inhibition, and 80% increase in survival.